Onxeo Continues to Strengthen its Board of Directors
Retrieved on:
Tuesday, November 23, 2021
Senior, Euronext Paris, PARP, Risk, 2009 Davis Cup, Company, Merrill, Awareness, Professional, DNA, Nasdaq First North, Inflammation, COO, Therapy, Oligonucleotide, Gilead Sciences, Nasdaq Copenhagen, Neoplasm, Communication, GLOBE, CFO, Board of directors, Board, John C. Giraudo, Director, United, DDR, AMF, Arctic Response Company Group, Pharmaceutical industry, Management, Vaccine
Paris (France), Nov. 23, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the appointment of Bryan Giraudo as independent member of the Board of Directors, replacing Thomas Hofstaetter after three mandates.
Key Points:
- Prior to joining LEERINK Partners in 2009, Mr Giraudo was a Managing Director in Merrill Lynchs Global Healthcare Investment Banking Division.
- Bryan Giraudo, new independent member of the Board of Directors of Onxeo, declared: "I am thrilled to join Onxeos Board of Directors, comprising outstanding experts in different clinical and strategic fields.
- Shefali Agarwal, Chairwoman of the Board of Directors of Onxeo, commented: On behalf of the entire Board of Directors I would like to thank Thomas Hofstaetter for his important contribution to the development of ONXEO during the past nine years.
- Judith Greciet, Chief Executive Officer of Onxeo, concluded: "With Bryan joining our Board of Directors today, I am glad that our Company was able to attract such an outstanding group of seasoned professionals.